Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
172
Recruiting, any sponsor type, condition "Alzheimer"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting172
- Completed1,051
172 trials
Showing 1 to 25, recently updated first.
National Institute of Mental Health (NIMH)NIH
NCT07169630 · 90 participants (planned) · Start Nov 25, 2026 · Primary completion Apr 11, 2029
Drug: 18F-PF974; 18F-florbetaben · For: Alzheimer s Disease; Mild Cognitive Impairment; Healthy
Sites: Bethesda, Maryland
- Neuroplasticity Enhancement From Cognitive Training Reinforced by PsilocybinPivotal-lookingRecruiting
National Institute on Aging (NIA)NIH
NCT07721467 · 200 participants (planned) · Start Nov 25, 2026 · Primary completion Dec 31, 2030
Drug: Psilocybin · For: Alzheimer's Disease
Sites: Baltimore, Maryland
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT07279740 · 12 participants (planned) · Start Jun 2, 2026 · Primary completion Oct 1, 2027
Drug: Methylphenidate (MPH) · For: Alzheimer s Disease; Alzheimer Dementia (AD); Alzheimer Dementia and 3 more
Sites: Toronto, Canada
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT07889349 · 50 participants (planned) · Start Nov 9, 2026 · Primary completion Jan 2027
Drug: SHR 3201 Injection; SHR 3201 Placebo. · For: Alzheimer's Disease
Sites: Hefei, China
Eidos Therapeutics, a BridgeBio companyIndustry
NCT07695701 · 150 participants (planned) · Start Jul 28, 2026 · Primary completion Aug 2030
Drug: Acoramidis (AG10) oral tablet · For: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloidosis; Amyloid Cardiomyopathy and 1 more
Sites: Baltimore, Maryland; St Louis, Missouri; Philadelphia, Pennsylvania · 9 sites in all
- A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPivotal-lookingRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT05552157 · 280 participants (planned) · Start Nov 22, 2024 · Primary completion Mar 30, 2034
Drug: Remternetug (SC); Matching Placebo (Remternetug) · For: Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 37 sites in all
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPivotal-lookingRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT06647498 · 280 participants (planned) · Start Nov 22, 2024 · Primary completion Mar 2034
Drug: Remternetug; Matching Placebo (Remternetug) · For: Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 36 sites in all
- A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07843459 · 111 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 2028
Drug: LY4560736; LY4560736 and 2 more · For: Healthy Volunteers; Alzheimer Disease; Amyloid and 2 more
Sites: Anaheim, California; Irvine, California; Los Alamitos, California · 19 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07214727 · 50 participants (planned) · Start Oct 15, 2025 · Primary completion Mar 6, 2030
Drug: ALN-5288; Placebo · For: Alzheimer's Disease
Sites: Montreal, Canada; Ottawa, Canada; Toronto, Canada · 13 sites in all
Alpha Cognition, IncIndustry
NCT07633470 · 150 participants (planned) · Start May 20, 2026 · Primary completion Apr 2027
Drug: Zunveyl® · For: Alzheimer Disease
Sites: Irvine, California; Orange, California; Aventura, Florida · 26 sites in all
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT06014424 · 40 participants (planned) · Start Sep 27, 2023 · Primary completion Dec 2027
Drug: CBD; Placebo · For: Alzheimer Disease
Sites: Calgary, Canada; London, Canada; Toronto, Canada · 5 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06976203 · 586 participants (planned) · Start Jul 21, 2025 · Primary completion Sep 11, 2028
Drug: KarXT; KarX-EC · For: Alzheimer's Disease
Sites: Fullerton, California; Irvine, California; Los Angeles, California · 129 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06976216 · 586 participants (planned) · Start Jul 14, 2025 · Primary completion Sep 11, 2028
Drug: KarXT; KarX-EC · For: Alzheimer's Disease
Sites: Long Beach, California; Redlands, California; Basalt, Colorado · 119 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07787182 · 68 participants (planned) · Start Oct 10, 2026 · Primary completion Jan 2028
Drug: LY4405094; LY4405094 and 2 more · For: Healthy Volunteers; Alzheimer Disease; Amyloid and 1 more
Sites: Anaheim, California; Irvine, California; Los Alamitos, California · 19 sites in all
- Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07781657 · 450 participants (planned) · Start Nov 10, 2026 · Primary completion Nov 1, 2029
Drug: RO7568282; Placebo · For: Alzheimer's Disease
Sites: Stuart, Florida; Wellington, Florida; Winter Park, Florida · 12 sites in all
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPivotal-lookingRecruiting
MapLight TherapeuticsIndustry
NCT06887192 · 300 participants (planned) · Start Aug 15, 2025 · Primary completion Dec 2027
Drug: ML-007C-MA; Placebo · For: Psychosis Associated With Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 69 sites in all
Acta PharmaceuticalsIndustry
NCT07690228 · 72 participants (planned) · Start Sep 23, 2026 · Primary completion Nov 2027
Drug: GSM-779690T; Placebo · For: Healthy Adult Participants; Alzheimer Disease
Sites: Melbourne, Australia
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT05231785 · 60 participants (planned) · Start Feb 4, 2022 · Primary completion Jan 11, 2029
Drug: ALN-APP; Placebo · For: Early-Onset Alzheimer Disease
Sites: La Jolla, California; Indianapolis, Indiana; Montreal, Canada · 8 sites in all
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06937229 · 650 participants (planned) · Start Dec 2, 2025 · Primary completion Jun 22, 2029
Drug: KarXT; KarX-EC · For: Alzheimer Disease; Agitation
Sites: Chandler, Arizona; Scottsdale, Arizona; Anaheim, California · 255 sites in all
- Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary TauopathiesPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT07221344 · 160 participants (planned) · Start Nov 18, 2025 · Primary completion Jun 2027
Drug: ARO-MAPT-SC; Placebo · For: Alzheimer Disease; Tauopathies; Frontotemporal Dementia and 1 more
Sites: East York, Canada; Toronto, Canada; Montreal, Canada · 4 sites in all
- A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07717411 · 1,600 participants (planned) · Start Oct 2, 2026 · Primary completion Jul 30, 2032
Drug: Trontinemab; Placebo · For: Alzheimer's Disease
Sites: Irvine, California; Long Beach, California; Los Angeles, California · 72 sites in all
- A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07688213 · 160 participants (planned) · Start Jul 28, 2026 · Primary completion Jul 31, 2029
Drug: SAR448851; Placebo · For: Dementia, Alzheimer's Type; Alzheimer's Disease
Sites: Long Beach, California; Oakland, California; Naples, Florida · 32 sites in all
- Nabilone for Agitation Blinded Intervention TrialPivotal-lookingRecruiting
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04516057 · 112 participants (planned) · Start Feb 1, 2021 · Primary completion Dec 2027
Drug: Nabilone · For: Alzheimer Disease; Agitation
Sites: Calgary, Canada; Hamilton, Canada; London, Canada · 8 sites in all
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07011732 · 426 participants (planned) · Start Jul 10, 2025 · Primary completion Nov 24, 2028
Drug: Xanomeline/Trospium Chloride Capsule; Xanomeline Enteric Capsule and 1 more · For: Alzheimer Disease
Sites: Scottsdale, Arizona; Anaheim, California; Fresno, California · 162 sites in all
Fudan UniversityAcademic, hospital or other
NCT07923812 · 3,000 participants (planned) · Start Oct 26, 2026 · Primary completion Jun 30, 2027
Drug: Disease-Modifying Therapy · For: Alzheimer's Disease (AD)
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.